Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $158.87 USD
Change Today -0.57 / -0.36%
Volume 1.2M
AMGN On Other Exchanges
Hong Kong
Sao Paulo
As of 10:27 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/15 - $173.60
52 Week Low
05/9/14 - $109.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

17,900 Employees
Last Reported Date: 02/19/15
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.4M
Executive Vice President of Operations
Total Annual Compensation: $943.0K
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $899.9K
Compensation as of Fiscal Year 2014.

amgen inc (AMGN) Key Developments

Amgen Inc. Issues Senior Notes

On May 1, 2015, Amgen Inc. issued and sold $750,000,000 of its 2.125% Senior Notes due 2020, $500,000,000 of its 2.700% Senior Notes due 2022, $1,000,000,000 of its 3.125% Senior Notes due 2025 and $1,250,000,000 of its 4.400% senior notes due 2045. The notes are registered under an effective registration statement on form S-3 (Registration No. 333-194103). The 2020 Notes will bear interest at a rate of 2.125% per annum, the 2022 Notes will bear interest at a rate of 2.700% per annum, the 2025 Notes will bear interest at a rate of 3.125% per annum and the 2045 Notes will bear interest as a rate of 4.400% per annum, which, in each case, shall be payable semi-annually in arrears on each May 1 and November 1, beginning on November 1, 2015. The 2020 Notes, the 2022 Notes, the 2025 Notes and the 2045 Notes will mature on May 1, 2020, May 1, 2022, May 1, 2025 and May 1, 2045, respectively.

Amgen Announces FDA Advisory Committee Meeting to Review Repatha as Treatment for High Cholesterol

Amgen Inc. announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration will review data supporting the company's Biologics License Application (BLA) for RepathaTM (evolocumab) for the treatment of high cholesterol at a meeting on June 10, 2015. Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood. The EMDAC will review results from clinical trials in support of the BLA for Repatha, which is based on data from approximately 6,800 patients, including more than 4,500 patients with high cholesterol in 10 Phase 3 trials. The Phase 3 studies evaluated the safety and efficacy of Repatha in patients with elevated cholesterol, including patients on statins with or without other lipid-lowering therapies; patients who cannot tolerate statins; patients with heterozygous familial hypercholesterolemia and patients with homozygous familial hypercholesterolemia, a rare and serious genetic disorder.

Amgen Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year Ending December 31, 2015

Amgen reported unaudited consolidated earnings results for the first quarter ended March 31, 2015 . The company reported that its net income of $1.62 billion or $2.11 per share, compared with the prior-year period's $1.07 billion or $1.40 per share. Non-GAAP net income was $1.91 billion or $2.48 per share, versus $1.43 billion or $1.87 per share in the same quarter the previous year. Revenue was $5 billion, up 11% from $4.52 billion in the same quarter last year. Adjusted Operating Income was $2,499 million compared to $1,860 m n a year ago. Adjusted Net Income was $1,911 million compared to $1,438 million a year ago. Adjusted EPS was $2.48 compared to $1.87 a year ago. GAAP Operating Income was $2,022 million compared to $1,364 million a year ago. Operating Cash Flow was $1.3 billion compared to $1.1 billion a year ago. Capital Expenditures were $0.1 billion compared to $0.2 billion a year ago. Income before income taxes was $1,876 million compared to $1,204 million a year ago. Adjusted income before income taxes was $2,303 million compared to $1,700 million a year ago. For fiscal Year Ending December 31, 2015, the company now expects adjusted EPS of $9.35 - $9.65 on revenue of $20.9 billion - $21.3 billion. This is revised from the previous guidance of adjusted EPS in the range of $9.05 - $9.40 and revenue in the range of $20.8 billion to $21.3 billion. Adjusted tax rate to be in the range of 18% to 19%. This excludes the benefit of the federal R&D tax credit, which has not yet been extended for 2015. Capital expenditures to be approximately $800 million. GAAP tax rate to be in the range of 13% to 15%. GAAP diluted EPS guidance of $7.78-$8.13.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $158.96 USD -0.48

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.68 USD -0.1837
Bristol-Myers Squibb Co $64.88 USD -0.15
Eli Lilly & Co $72.05 USD +0.14
Medtronic PLC $74.60 USD -0.31
Novo Nordisk A/S kr366.10 DKK -4.50
View Industry Companies

Industry Analysis


Industry Average

Valuation AMGN Industry Range
Price/Earnings 21.9x
Price/Sales 6.0x
Price/Book 4.7x
Price/Cash Flow 21.6x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at